Equillium, Inc. (EQ)
NASDAQ: EQ · IEX Real-Time Price · USD
1.670
+0.110 (7.05%)
At close: May 3, 2024, 4:00 PM
1.660
-0.010 (-0.60%)
After-hours: May 3, 2024, 4:57 PM EDT
Equillium Revenue
In the year 2023, Equillium had annual revenue of $36.08M with 128.97% growth. Revenue in the quarter ending December 31, 2023 was $9.21M, a -41.55% decrease year-over-year.
Revenue (ttm)
$36.08M
Revenue Growth
+128.97%
P/S Ratio
1.63
Revenue / Employee
$820,091
Employees
44
Market Cap
58.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
Dec 31, 2022 | 15.76M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEQ News
- 4 weeks ago - Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis - Business Wire
- 5 weeks ago - Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights - Business Wire
- 6 weeks ago - Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference - Business Wire
- 4 months ago - Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease - Business Wire
- 6 months ago - Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology - Business Wire
- 6 months ago - Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates - Business Wire
- 6 months ago - Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology - Business Wire